ClC-1 Inhibitor Restores Muscle Function in Aged Rodents as Study Pinpoints NaV1.4 Loss
Updated
Updated · Medscape · Oct 28
ClC-1 Inhibitor Restores Muscle Function in Aged Rodents as Study Pinpoints NaV1.4 Loss
3 articles · Updated · Medscape · Oct 28
Summary
Journal of Clinical Investigation data linked sarcopenia-related weakness to failed nerve-to-muscle signaling, not just shrinking muscle, and showed a ClC-1-blocking compound restored function in aged rodents.
Older adults in the study showed breakdown at the neuromuscular junction, where depleted NaV1.4 sodium channels left muscles unable to respond fully to nerve signals.
Rather than replacing NaV1.4, partial ClC-1 inhibition made muscle fibers more excitable and bypassed that signaling failure; the NMD Pharma compound already has FDA orphan-drug status for rare neuromuscular disorders.
Researchers said human translation still faces years of trials, unclear sarcopenia definitions, and questions over whether benefits would meaningfully improve strength or physical function.
For now, the findings reinforce current care: assess chair-stand and gait performance, address nutrition and medical causes, and use resistance training as the main treatment.